IMULAN Launches LeukoSTAT™; ImSAIDS® – Based Technology

By admin | November 29, 2009

(November 12, 2009) - Imulan BioTherapeutics, LLC (IMULAN) announced the release of LeukoSTAT™; a nutritional product containing a newly recognized class of naturally occurring amino acid complexes referred to as ImSAIDs (Immune Selective Anti-Inflammatory Derivatives). Originally discovered as important components of saliva, ImSAIDS have been shown to target leukocytes, thereby going right to the source of inflammation regardless of the cause, making it a useful product for the veterinarian. ImSAIDs have demonstrated positive effects in models of pancreatitis, sepsis, asthma, anaphylaxis, allergic reactions and spinal trauma.

Dr. Craig Woods, CEO of IMULAN, stated, “We are seeing science move away from traditional drugs which focus on blocking enzymes such as cyclo-oxygenase, towards totally natural technologies as exemplified by the ImSAIDS. Researchers can now develop products which modify the cells that make the enzymes, essentially going right to the source of the problem. This becomes a much more powerful and comprehensive tool with broad applications.”

Imulan develops immune regulating, naturally-occurring substance for veterinary medicine. Imulan’s primary focus is to combine peptide pharmacology with immunology to manage inflammatory, infectious and immune mediated diseases in companion and production animals.

Visit www.IMULAN.com or www.LeukoSTAT.com for more information.

Posted in FIV / FeLV Treatment Aid | Comments closed

IMULAN to Present Feline Stomatitis Data at 2009 Veterinary Dental Forum

By admin | November 28, 2009
St. Joseph, MO. – (October 21st, 2009)   Imulan BioTherapeutics, LLC (IMULAN) has been selected to present their most recent findings on feline stomatitis at this year’s Veterinary Dental Forum.  The session entitled “T-Cell Receptor Peptide Technology for Feline Stomatitis” will be presented by Dr. Craig Woods.  The T-Cell Receptor (TCR) technology, a biologic immune modulator, is being developed by IMULAN for immune based disorders including stomatitis.  Feline stomatitis, often referred to as lymphocytic plasmacytic stomatitis or gingivostomatitis, is a disorder that results in oral inflammation.  The TCR technology affects T-helper cells, which are immune cells implicated in feline stomatitis. 
About Feline Stomatitis: Feline stomatitis is a frustrating and prevalent condition in cats.  Although there is no known single cause of this condition, the outcome is inflammation of the oral cavity and gingival tissue.  The inflammation is a result of immune cells infiltrating the tissue and is thought to be an imbalance in a specific type of lymphocyte, called the T-helper cell.  Treatment for feline stomatitis is often limited and may consist of steroids, antibiotics, anti-inflammatories, and/or surgery.
About the TCR peptides: T-Cell Receptor peptides are immune modulating biologics designed to restore immune function and normalize cytokine profiles by precisely regulating T-helper cell activity.  The peptides are undergoing evaluation for atopic dermatitis, feline stomatitis, and various other disorders including viral infections, cardiac disease, and fungal infections.
About IMULAN: Imulan develops unique, precision immune regulating compounds for veterinary medicine.  IMULAN’s primary focus is on biological strategies to treat infectious, autoimmune, and immune mediated diseases in small and large animal medicine.  In 2008, IMULAN licensed Lymphocyte T-Cell Immunomodulator as a conditionally approved treatment aid for cats infected with feline leukemia and immunodeficiency virus.  For more information about Imulan, please visit www.IMULAN.com. ###
Posted in In the News, Press Releases | Tagged , | Comments closed

IMULAN Expands Veterinary apSTAR Cancer Program

By admin | November 28, 2009
Imulan BioTherapeutics, LLC has extended the term of their exclusive license agreement with ImmunoPhotonics Inc.; for the veterinary cancer laser system based on on-going clinical trials in dogs and cats. The new portable laser device, termed apSTAR (Autologous Patient Specific Tumor Antigen Response), uses a specific wavelength to activate an immune response against the tumor cells. IMULAN’s subsidiary, Veterinary Cancer Therapeutics, is focused on hemangiosarcoma, fibrosarcoma, mast cell tumors, melanoma, osteosarcoma, and other prevalent cancers in dogs, cats and horses. In previous in vivo cancer models, apSTAR has shown the ability to induce long term tumor immunity and improve primary and metastatic tumor regression.Immunophotonics, Inc. was established in 2008 by a team of experts in laser physics and immunotherapy as a US-based research-oriented company whose main objective is to develop and introduce Laser-assisted Immunotherapy, a promising new treatment method for metastatic tumors.

Imulan develops unique, precision immune regulating compounds for infectious, autoimmune, and immune mediated diseases in small and large animal medicine. For more information about Imulan, please visit ,a href=”http://www.imulan.com”>www.imulan.com.

Posted in In the News, Press Releases | Tagged , , | Comments closed

IMULAN to Present Feline Stomatitis Data at 2009 Veterinary Dental Forum

By admin | October 21, 2009

St. Joseph, MO. – (October 21st, 2009)   Imulan BioTherapeutics, LLC (IMULAN) has been selected to present their most recent findings on feline stomatitis at this year’s Veterinary Dental Forum.  The session entitled “T-Cell Receptor Peptide Technology for Feline Stomatitis” will be presented by Dr. Craig Woods.  The T-Cell Receptor (TCR) technology, a biologic immune modulator, is being developed by IMULAN for immune based disorders including stomatitis.  Feline stomatitis, often referred to as lymphocytic plasmacytic stomatitis or gingivostomatitis, is a disorder that results in oral inflammation.  The TCR technology affects T-helper cells, which are immune cells implicated in feline stomatitis. 

About Feline Stomatitis: Feline stomatitis is a frustrating and prevalent condition in cats.  Although there is no known single cause of this condition, the outcome is inflammation of the oral cavity and gingival tissue.  The inflammation is a result of immune cells infiltrating the tissue and is thought to be an imbalance in a specific type of lymphocyte, called the T-helper cell.  Treatment for feline stomatitis is often limited and may consist of steroids, antibiotics, anti-inflammatories, and/or surgery.

About the TCR peptides: T-Cell Receptor peptides are immune modulating biologics designed to restore immune function and normalize cytokine profiles by precisely regulating T-helper cell activity.  The peptides are undergoing evaluation for atopic dermatitis, feline stomatitis, and various other disorders including viral infections, cardiac disease, and fungal infections.

Posted in In the News, Press Releases | Comments closed

IMULAN Prepares To Initiate Trials For Atopic Dermatitis In Dogs

By admin | August 9, 2009

IMULAN BioTherapeutics, LLC announced they are prepared to commence with regulated trials to complete work on the T-Cell Receptor peptide immunomodulator, for atopic dermatitis in dogs. Canine atopic dermatitis is a very prevalent condition in dogs, thought to affect up to 5 percent of the dog population. Clinical signs of atopic dermatitis include pruritus (itching) and an increase in topical skin infections such as staphylococcal pyoderma. The T-Cell Receptor peptides have previously shown significant improvement in dogs with severe atopic dermatitis.

T-Cell Receptor peptides target T-helper cells: immune cells that are key players in atopic and allergic dermatitis. T-helper cells are central regulators of immune function and their imbalance is implicated in a variety of disorders including atopy, asthma, stomatitis, and various infections.

Dr. Daniel Gingerich, CSO of IMULAN, stated, “We are excited to begin our final phase of work that will be used in support of a product approval. We are currently setting up multiple centers around the country to participate in our clinical program and to help acquire the necessary data for submission.”

Dr. Craig Woods, CEO of IMULAN, states, “This is an exciting time for IMULAN, a small biopharmaceutical company focused on major diseases in veterinary medicine such as allergic skin disorders. We believe our immune modulating approach will be far superior to traditional immunosuppressive drugs and advance a brand new technology platform to market.”

Posted in In the News, Press Releases | Comments closed

IMULAN Licenses Breakthrough Cancer Technology from IMMUNOPHOTONICS

By admin | June 8, 2009

 

St. Joseph, MO. – (June 9th, 2009)   Imulan BioTherapeutics, LLC (Imulan) announced they have licensed the exclusive global veterinary rights to a breakthrough, patented laser technology from ImmunoPhotonics Inc. for cancer treatment.  The new laser device, termed apSTAR after Autologous Patient Specific Tumor Antigen Response, induces a potent immunological response to tumor cells and their antigens, thereby provoking long term tumor immunity and improving primary and metastatic tumor regression.  Imulan recently announced the formation of Veterinary Cancer Therapeutics, their oncology division, which has already started establishing cancer centers around the country using the apSTAR medical device technology.

 Dr. Craig Woods, CEO of Imulan and Veterinary Cancer Therapeutics, stated, “We are very excited to be working with ImmunoPhotonics to advance this oncology breakthrough.  With this collaboration, we are standing on the edge of changing the general approach to cancer treatment.  The data are astonishing and should have a major impact for veterinarians in the near future.  apSTAR will help shift the emphasis towards immune-based therapies and away from cytotoxic drug or radiation therapy for many types of cancer.”

Dr. Tomas Hode of ImmunoPhotonics, Inc. stated, “We are very pleased to have formed this collaboration with IMULAN. Our method is showing wonderful results and is very soon ready to be released on the market. IMULAN is a company with a very strong portfolio and is a frontrunner in the field, so we could not have found a better partner with whom to launch this exciting new product.”

About apSTAR: apSTAR is a patented medical device technology that employs a specific laser wavelength to liberate tumor specific antigens and activate an immune response against the tumor cells.  Numerous published studies have shown apSTAR to improve the rate of primary and metastatic tumor regression and induce long term tumor immunity.  The apSTAR device is available on a limited basis in the United States, with full scale production scheduled for later this year.

About ImmunoPhotonics, Inc: Immunophotonics, Inc. was established in 2008 by a team of experts in laser physics and immunotherapy as a US-based research-oriented company with a main objective to develop and introduce Laser-assisted Immunotherapy, a promising new treatment method for metastatic tumors. 

 

Posted in In the News, Press Releases | Comments closed

IMULAN Reports Positive Findings for Canine Dilated Cardiomyopathy

By admin | May 12, 2009

St. Joseph, MO. – (May 12th, 2009)   Imulan BioTherapeutics, LLC (IMULAN) announced encouraging echocardiographic findings from a recent pilot trial using their T-Cell Receptor (TCR) peptides for canine dilated cardiomyopathy.  The study was supported by a grant from the American Kennel Club Canine Health Foundation and conducted by veterinary cardiologists in dogs with stable but confirmed dilated cardiomyopathy.  Previous work in mice and turkeys demonstrated IMULAN’s TCR peptides have profound effects on infectious and drug-induced cardiomyopathy, and appear to induce remodeling of cardiac tissue by modulating the immune system.  Larger studies are being designed to further investigate these findings.

Dr. Daniel Gingerich, CSO of IMULAN stated, “For the first time, we may have documented the clinical relevance of the link between immune modulation and therapeutic intervention in canine cardiomyopathy.  Our findings suggest an improvement in cardiac function after immunization with our peptides, an effect that has been observed with other species.  Although preliminary findings are encouraging, more work will be needed to confirm our findings and elucidate the optimal approach to this devastating disease.”

Dr. Craig Woods, CEO of IMULAN went on to state, “There is growing evidence that certain cardiac diseases are accompanied by changes in lymphocyte populations.  Lymphocytes, which produce a variety of cell signals, may directly influence cardiac fibroblasts and thereby affect cardiac compensation.  We are hopeful that this research will lead to major cardiovascular breakthroughs within the next few years.”

Dr. Christine Haakenson, Director of Research Program Development, AKC Canine Health Foundation stated, “I look forward to following the development of this research into a treatment that will improve the life of dogs inflicted with dilated cardiomyopathy.”

 About the TCR peptides: T-Cell Receptor Peptide Vaccines are immune modulating biologics designed to regulate T-helper cell activity, including restoring immune function in aged animals and normalizing Th1/Th2 cytokine signaling profiles.  The TCR peptide platform is being developed for cardiovascular, infectious disease, and immune mediated diseases.  Recently, evidence is implicating the immune system as playing a role in cardiomyopathy which could lead to a new class of compounds to treat this disease.

Posted in In the News, Press Releases | Comments closed

IMULAN Receives AKC Grant to Develop Atopic Dermatitis Diagnostic

By admin | April 1, 2009

Prescott, AZ and St. Joseph, MO. – (April 1, 2009)   Imulan BioTherapeutics, LLC (IMULAN) announced they received a grant from the American Kennel Club Canine Health Foundation entitled “Development of a Diagnostic Method for Canine Atopic Dermatitis”.  This grant is based on IMULAN’s T-Cell Receptor (TCR) peptide technology platform, the same platform being used to develop a therapeutic vaccine (immunomodulator) for canine atopic dermatitis.  Recently, IMULAN completed a study demonstrating that vaccination with their TCR peptides significantly improved the clinical status of dogs with severe atopic dermatitis.

Dr. Daniel Gingerich, CSO of IMULAN stated, “We are grateful to the American Kennel Club for their research support for diseases like atopic dermatitis.  This project will examine immunological markers in blood to try and better identify patients with atopic dermatitis.  If successful, IMULAN’s atopic dermatitis diagnostic could be available from IMULAN’s reference laboratory early next year.”

Dr. Craig Woods, CEO of IMULAN went on to state, “The TCR peptides appear to have a dual purpose, which can be diagnostic and therapeutic in application, similar to antigens.  Creating a diagnostic for atopic dermatitis is an exciting prospect for veterinary medicine, one which may be useful in identifying the optimal treatment program for each patient.”

About Canine Atopic Dermatitis: Canine atopic dermatitis is a very prevalent condition in dogs, thought to affect up to 5% of the dog population.  Dogs with atopic dermatitis are comparative to human atopic dermatitis, including alterations in immune profiles and sensitivity to allergens.  Clinical signs of atopic dermatitis include pruritis (itching) and an increase in topical skin infections such as staphylococcal pyoderma.

 About the TCR peptides: T-Cell Receptor peptides are immune modulating biologics designed to restore immune function and normalize cytokine profiles by precisely regulating T-helper cell activity.  The peptides are undergoing formal approval process for atopic dermatitis and feline stomatitis but have also evidenced promise for viral infections, cardiac disease, and fungal infections.

Posted in FIV / FeLV Treatment Aid, In the News, Press Releases | Comments closed

IMULAN Forms Veterinary Cancer Therapeutics

By admin | March 11, 2009

Prescott, AZ and St. Joseph, MO. – (March 5th, 2009)   Imulan BioTherapeutics, LLC (IMULAN) announced they have formed a new company, Veterinary Cancer Therapeutics (www.VetCancer.com) to advance their comparative veterinary oncology programs and commercialize several new immune activating technologies for treating cancer.  Veterinary Cancer Therapeutics will provide veterinarians access to their technology platforms by creating a treatment network.  The company will be located at the IMULAN headquarters within the Christopher S. “Kit” Bond Science and Technology Incubator, St. Joseph, MO and will be opening a new laboratory to advance their tumor biology and comparative oncology science programs.

 Dr. Craig Woods, CEO of IMULAN and Veterinary Cancer Therapeutics, stated, “Mother Nature designed the most powerful tool against cancer, being the immune system.  Many forms of cancer trick the immune system by producing factors that create a chemical camouflage and thus evade immune detection.  IMULAN is currently working on cutting edge ways of making cancer visible to immune cells, giving the patient the upper hand.”

Veterinary Oncology: Like humans, dogs and cats develop numerous forms of cancer.  Lymphoma, fibrosarcoma, mast cell tumors (mastocytoma), and adenocarcinomas represent some of the more prevalent forms of cancers in companion animals. 

About Veterinary Cancer Therapeutics: Veterinary Cancer Therapeutics is owned by IMULAN BioTherapeutics, LLC and was formed by licensed veterinarians with backgrounds in clinical practice, comparative medicine, and immunology. IMULAN is a leader in therapeutic immunology and recently licensed and commercialized Lymphocyte T-Cell Immunomodulator, the first treatment aid for Feline Leukemia Virus and Feline Immunodeficiency Virus.     For more information about Veterinary Cancer Therapeutics, please visit www.vetcancer.com. ###

Posted in FIV / FeLV Treatment Aid, In the News, Press Releases | Comments closed

Get 1 Free Pack of Feline Leukemia and Feline Immunodeficiency Virus Treatment Aid from IMULAN

By Dr. Craig Woods | May 1, 2008
Save on Lymphocyte T-Cell Immunomodulator (LTCI) from IMULAN BioTherapeutics, the first and only conditionally approved treatment aid in the United States for Feline Leukemia Virus (FeLV) and Feline Immunodeficiency Virus (FIV or Feline AIDS) infections.

Prescott, Arizona (PRWEB) May 1, 2008 — IMULAN BioTherapeutics (IMULAN) announced a “Buy 1 Pack, Get 1 Pack Free” promotion on Lymphocyte T-Cell Immunomodulator (LTCI), the first and only approved treatment aid in the United States for Feline Leukemia Virus (FeLV) and Feline Immunodeficiency Virus (FIV or Feline AIDS) infections.  For every order a veterinarian places for LTCI before June 15, 2008, IMULAN will match that order with free product.

Dr. Craig Woods, CEO of IMULAN, stated, “In appreciation for making our launch of LTCI a tremendous success, IMULAN is pleased to offer this promotion to help cats infected with FeLV and FIV.”

Lymphocyte T-Cell Immunomodulator is a naturally occurring substance produced by the body.  In previous studies, Lymphocyte T-Cell Immunomodulator has demonstrated improvement in the clinical symptoms and lymphocyte counts in cats infected with FeLV and FIV. 

LTCI and the “Buy 1 Pack, Get 1 Pack Free” promotion are only available through licensed veterinarians in the United States.  Cat owners are encouraged to contact their veterinarian for additional information about LTCI, feline leukemia virus (FeLV), or feline immunodeficiency virus (FIV or Feline AIDS) infections.

About Lymphocyte T-Cell Immunomodulator:  LTCI is a conditionally approved treatment aid for cats infected with Feline Leukemia Virus (FeLV) and/or Feline Immunodeficiency Virus (FIV). Conditional licenses are granted by the United States Department of Agriculture Center for Veterinary Biologics to products that have met reasonable expectation of efficacy, have demonstrated purity, and passed safety testing. LTCI is manufactured by T-Cyte Therapeutics, Inc. and is exclusively distributed by IMULAN BioTherapeutics, LLC. 

About IMULAN BioTherapeutics:  IMULAN is a privately held bioscience company focused on providing innovative solutions for complex animal diseases. IMULAN’s policy is to provide veterinarians access to conditionally approved products for diseases where no current approved therapy is available. IMULAN’s products give animal owners better solutions for their pet’s diseases. 

For more information, visit www.IMULAN.com

Contact:
Dr. Craig Woods, CEO
IMULAN BioTherapeutics
877.892.9595
cwoods@imulan.com

Posted in FIV / FeLV Treatment Aid, Press Releases | Comments closed